Adagrasib Patent Expiration
Adagrasib is Used for treating locally advanced or metastatic non-small cell lung cancer in adult patients with a specific KRAS mutation who have already undergone prior systemic therapy. It was first introduced by Bristol Myers Squibb Co
Adagrasib Patents
Given below is the list of patents protecting Adagrasib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Krazati | US12383503 | Adagrasib Solid Pharmaceutical Compositions | Aug 21, 2043 | Bristol |
| Krazati | US12653789 | Adagrasib Solid Pharmaceutical Compositions | Aug 21, 2043 | Bristol |
| Krazati | US12281113 | Crystalline forms of a KRas G12C inhibitor | Sep 10, 2041 | Bristol |
| Krazati | US12336995 | Combination Therapies | Feb 05, 2041 | Bristol |
| Krazati | US10689377 | KRas G12C inhibitors | May 17, 2037 | Bristol |
Adagrasib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Adagrasib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
